PROFESSIONAL EDITION

The largest community of pharma leaders

Bayer Pharmaceuticals Taps Two Leaders for New Roles in the U.S.

WHIPPANY, N.J.–()–Today, Bayer announced that two of its top Pharmaceutical executives will take on new leadership roles within the division to advance its position in key therapeutic areas.

Nelson Ambrogio, formerly the Senior Vice President, General Manager of Women’s Healthcare has been appointed to the role of Senior Vice President, General Manager of Oncology. John Berrios, formerly Vice President of Commercial Operations, will become the Senior Vice President, General Manager of Women’s Healthcare.

Ambrogio and Berrios will both serve on the U.S. Pharmaceutical Leadership Team and report directly to Sebastian Guth, Bayer’s President of Pharmaceuticals, Americas Region.

Nelson and John are passionate, well-respected leaders in the pharmaceutical industry and have a proven track record of launching products, developing rising leaders and driving growth,” said Guth. “The U.S. Pharmaceuticals Business is central to Bayer’s success. I’m confident that under their leadership, the Oncology and Women’s Healthcare franchises will continue on a growth path and further strengthen our overall business in the U.S.”

Prior to his current appointment as SVP and GM of Oncology, Ambrogio was the SVP and GM of the Women’s Healthcare business in the U.S, overseeing the Sales and Marketing teams for the company’s contraceptive franchise. Prior to WHC, Ambrogio held multiple leadership positions within Bayer worldwide, including General Manager of Bayer in Australia and New Zealand (2015-2019), Managing Director of Bayer in Portugal (2012-2015), Head of the General Medicine business in Brazil (2010-2012) and Executive Board Support of Strategy and Human Resources in Germany (2007-2010). Ambrogio began his career in Sales and Marketing at Schering in Uruguay, South America. He holds a bachelor’s degree from the Universidad del Valle de Mexico, and a Master’s of Business Administration from the Business School Sao Paulo.

After five years at Bayer, Berrios will lead the Women’s Healthcare business in the U.S. starting May 1. Since joining Bayer in 2016, Berrios has held multiple leadership roles in market access and operations. In his previous role, as Vice President of Commercial Operations, he led enterprise-wide operations for the pharmaceutical division, as well as advanced the company’s digital transformation by building a best-in-class in-house media team. Most recently, Berrios successfully integrated a new digital customer engagement program across commercial, market access and medical.

Prior to joining Bayer, Berrios spent more than 15 years at AstraZeneca in various roles, including sales, market access, and marketing positions. He served as the Senior Director of Patient Engagement, where he was responsible for leading the marketing and patient engagement programs across the company’s portfolio including cardiovascular, diabetes, respiratory, specialty and oncology divisions.

Berrios also holds an MBA from St. John’s University and earned his bachelor’s degree from the University of New York at Albany.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Source

Recent Articles